Highlights
$Harrow (HROW.US)$ Second Quarter 2024 and Recent Selected Highlights:
● Record revenues of $48.9 million
● GAAP net loss of $(6.5) million
● Adjusted EBITDA of $8.8 million
● Cash and cash equivalents of $71.0 million as of June 30, 2024
● IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024
● IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina practice group
● VEVYE® total prescriptions increased by 212% from the first quarter of 2024
● Anterior Segment revenues up over 40% from the first quarter of 2024
● Record quarterly revenues from Harrow’s ImprimisRx subsidiary
● Record revenues of $48.9 million
● GAAP net loss of $(6.5) million
● Adjusted EBITDA of $8.8 million
● Cash and cash equivalents of $71.0 million as of June 30, 2024
● IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024
● IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina practice group
● VEVYE® total prescriptions increased by 212% from the first quarter of 2024
● Anterior Segment revenues up over 40% from the first quarter of 2024
● Record quarterly revenues from Harrow’s ImprimisRx subsidiary
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
